Seer Past Earnings Performance
Past criteria checks 0/6
Seer's earnings have been declining at an average annual rate of -32.4%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 56.9% per year.
Key information
-32.4%
Earnings growth rate
10.6%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | 56.9% |
Return on equity | -21.7% |
Net Margin | -517.8% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Seer, Inc. (NASDAQ:SEER) Just Reported, And Analysts Assigned A US$7.00 Price Target
Mar 02Newsflash: Seer, Inc. (NASDAQ:SEER) Analysts Have Been Trimming Their Revenue Forecasts
Nov 17We're Not Very Worried About Seer's (NASDAQ:SEER) Cash Burn Rate
May 19Companies Like Seer (NASDAQ:SEER) Are In A Position To Invest In Growth
Feb 06Analysts Have Lowered Expectations For Seer, Inc. (NASDAQ:SEER) After Its Latest Results
Nov 11Seer (NASDAQ:SEER) Is In A Good Position To Deliver On Growth Plans
Sep 15Seer stock tumbles aftermarket despite in-line Q2 earnings
Aug 09Companies Like Seer (NASDAQ:SEER) Are In A Position To Invest In Growth
Jun 02We Think Seer (NASDAQ:SEER) Can Afford To Drive Business Growth
Jan 17Seer: First Pick In Proteomics Portfolio
Sep 18Seer (NASDAQ:SEER) Is In A Good Position To Deliver On Growth Plans
Aug 30Sizing Up Seer
Jul 12We're Not Very Worried About Seer's (NASDAQ:SEER) Cash Burn Rate
May 13Seer reports Q1 results
May 10Is Seer, Inc. (NASDAQ:SEER) Popular Amongst Insiders?
Mar 04Seer, Bruker sign commercial agreement for proteomics
Jan 11Revenue & Expenses BreakdownBeta
How Seer makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 17 | -86 | 59 | 53 |
30 Sep 23 | 17 | -91 | 60 | 54 |
30 Jun 23 | 17 | -94 | 61 | 53 |
31 Mar 23 | 16 | -93 | 59 | 50 |
31 Dec 22 | 15 | -93 | 59 | 46 |
30 Sep 22 | 14 | -90 | 57 | 41 |
30 Jun 22 | 12 | -85 | 53 | 38 |
31 Mar 22 | 10 | -78 | 50 | 34 |
31 Dec 21 | 7 | -71 | 46 | 29 |
30 Sep 21 | 4 | -64 | 41 | 26 |
30 Jun 21 | 2 | -54 | 32 | 23 |
31 Mar 21 | 1 | -44 | 24 | 25 |
31 Dec 20 | 1 | -33 | 15 | 19 |
30 Sep 20 | 0 | -25 | 9 | 14 |
31 Dec 19 | 0 | -16 | 5 | 0 |
Quality Earnings: SEER is currently unprofitable.
Growing Profit Margin: SEER is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SEER is unprofitable, and losses have increased over the past 5 years at a rate of 32.4% per year.
Accelerating Growth: Unable to compare SEER's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SEER is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-9.3%).
Return on Equity
High ROE: SEER has a negative Return on Equity (-21.74%), as it is currently unprofitable.